Related Experiment Videos
Endometrial hyperplasia with secretory changes
Francisco Tresserra1, Maite Lopez-Yarto, Pedro J Grases
1Department of Pathology, Instituto Universitario Dexeus, 08017, Barcelona, Spain. 25865ftc@comb.es
Gynecologic Oncology
|March 22, 2003
Summary
Secretory changes in endometrial hyperplasia are uncommon but can occur, especially in premenopausal women using progestin hormone therapy. This finding may lead to misdiagnosis of endometrial cancer.
Area of Science:
- Gynecologic Pathology
- Reproductive Endocrinology
Background:
- Secretory changes are rarely observed in endometrial hyperplasia.
- Understanding these changes is crucial for accurate diagnosis and patient management.
Purpose of the Study:
- To investigate the clinicopathologic features of endometrial hyperplasia with secretory changes.
- To correlate hormonal treatment and menopausal status with morphological findings.
Main Methods:
- Retrospective review of 24 cases of endometrial hyperplasia with secretory changes.
- Correlation of clinical data (menopausal status, hormone treatment) with histological findings.
- Comparison with a control group of 24 women with conventional endometrial hyperplasia.
Main Results:
- 19 of 24 patients were premenopausal.
- Hormonal treatment, particularly with progestins, was noted in 17 patients.
- Endometrial adenocarcinoma was found in 7 patients, 5 concurrently with hyperplasia with secretory changes.
Conclusions:
- Secretory changes in the endometrium can occur in hyperplasia, predominantly in premenopausal women on progestin therapy.
- These changes pose a risk of misdiagnosis, potentially masking or mimicking other endometrial conditions.